006620 — DongKoo Bio & Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapValue Trap

Annual income statement for DongKoo Bio & Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	155,149	194,988	215,686	249,275	242,688
Cost of Revenue
Gross Profit	92,444	117,977	132,193	152,030	144,499
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	147,009	177,946	201,075	236,904	238,157
Operating Profit	8,140	17,042	14,611	12,371	4,531
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	11,333	7,916	14,741	3,819	61,413
Provision for Income Taxes
Net Income After Taxes	9,327	6,614	11,808	1,991	50,172
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,327	6,614	11,812	2,036	50,272
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,327	6,614	11,812	2,036	50,272
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	229	235	428	80.5	2,001
Dividends per Share